Fudan Zhangjiang (688505.SH): Injection FZ-P001 sodium for intraoperative visualization of known or suspected malignant lesions in lung cancer patients clinical trial accepted for review.

The Smart Finance APP News reported that Fudan Zhangjiang (688505.SH) has released an announcement. The company recently received an "Acceptance Notice" approved and issued by the National Medical Products Administration for the II phase clinical trial application of FZ-P001 sodium for injection used for visualizing malignant lesions in known or suspected lung cancer patients during surgery.